Inspire Medical Systems, Inc.
Financials
Valuation Metrics
Inspire Medical Systems, Inc.'s Market Cap is $1.50B. At end of 2025 it was $2.67B. Ranked #2246 of 3,112 in US market (top 72%), #1353 of 1,667 on NYSE (top 81%), #137 of 206 in Health Care Equipment & Services (top 67%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.50B | US#2,246/3,112 Sec#137/206 |
| Revenue | $915M | US#1,987/3,112 Sec#120/206 |
| Net Income | $131M | US#1,485/3,112 Sec#72/206 |
| Total Assets | $911M | US#2,487/3,112 Sec#133/206 |
| Net Assets | $792M | US#1,934/3,112 Sec#103/206 |
| Employees | 1,333 | US#1,219/3,112 Sec#98/206 |
| Value | ||
| P/E | 11.46x | US#343/3,112 Sec#7/206 |
| P/B | 1.90x | US#1,121/3,112 Sec#60/206 |
| P/S | 1.64x | US#1,051/3,112 Sec#77/206 |
| EV/EBITDA | 17.89x | US#1,730/3,112 Sec#73/206 |
| FCF Yield | 6.44% | US#997/3,112 Sec#43/206 |
| Profitability | ||
| ROE | 16.55% | US#766/3,112 Sec#34/206 |
| ROA | 14.39% | US#223/3,112 Sec#14/206 |
| Op. Margin | 5.61% | US#2,008/3,112 Sec#104/206 |
| Revenue Growth | 1.62% | US#2,092/3,112 Sec#157/206 |
| Earnings Growth | -477.47% | US#2,322/3,112 Sec#122/206 |
| Financial Health | ||
| Debt Ratio | 15.02% | US#175/3,112 Sec#15/206 |
| Total Debt | $30M | US#2,646/3,112 Sec#163/206 |
| FCF | $97M | US#1,679/3,112 Sec#104/206 |
| Cash | $99M | US#2,216/3,112 Sec#142/206 |
| Current Ratio | 6.34x | US#376/3,112 Sec#26/206 |
| Net Debt/EBITDA | -0.87x | US#337/3,112 Sec#23/206 |
| Performance | ||
| 1Y Return | -58.64% | US#3,044/3,112 Sec#198/206 |
| 1M Return | 11.08% | US#469/3,112 Sec#42/206 |
| From 52W High | -64.53% | US#2,973/3,112 Sec#198/206 |
| 1Y MDD | -73.31% | US#2,966/3,112 Sec#193/206 |
| Trading | ||
| Volume | 682,812 shares | US#1,826/3,112 Sec#136/206 |
| Trading Value | $36M | US#1,610/3,112 Sec#114/206 |
| Per Share | ||
| EPS | $5.02 | US#648/3,112 Sec#43/206 |
| BPS | $26.99 | US#951/3,112 Sec#58/206 |
Company Info
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.